Classic and Novel Adipokines as diagnostic biomarkers in NSCLC
2019
Introduction: Non small cell lung cancer (NSCLC) is the leading cause of cancer-related death globally. There is a tremendous interest in identifying novel biomarkers. The pathophysiological role of classic and novel adipokines in NSCLC is not yet fully understood and their value as diagnostic biomarkers is currently under research. Aim: To explore the diagnostic potential of classic (leptin, adiponectin) and novel adipokines (chemerin, plasminogen activator inhibitor-1 activity/PAI-1) in resectable NSCLC. Methods: In a large case-control study, circulating chemerin, adiponectin, leptin and PAI-1 were determined in 110 consecutive patients with resectable NSCLC and 110 healthy controls matched on age (± 5 years), gender and date of blood draw (± 1 month). Serum leptin, chemerin and adiponectin were determined by ELISA (BioVendor and ALPCO). Plasma PAI-1 activity was determined using Berichrom® PAI (Siemens). Results: Patients with NSCLC had significantly higher chemerin and PAI-1 activity (p Conclusion: Novel adipokines showed higher discriminative ability than classic adipokines in the NSCLC diagnosis. More prospective studies are required to assess the potential diagnostic significance of novel adipokines in NSCLC.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI